S-ClassAbout S-Class
C
CTMXAI Stock Diagnostic Report
CytomX gains Fast Track status for colorectal cancer antibody-drug conjugate
CytomX received fast-track designation for its antibody-drug conjugate (ADC) for colorectal cancer treatment.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$3.34Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support3.01 — echo this pre-calculated value verbatim, do NOT change it
Near-Term Resistance3.60 — echo this pre-calculated value verbatim, do NOT change it
02
FUNDAMENTALS
Financial & Fundamental Analysis
It is an event that contributes to accelerating development and increasing value of the core pipeline, rather than directly improving short-term financial performance.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $3.34 is located between the 20‑day support level ($3.01) and resistance level ($3.60), and given the misalignment of moving averages, it is a segment where one should carefully monitor whether the resistance will be broken.
Support3.01 — echo this pre-calculated value verbatim, do NOT change it
Resistance3.60 — echo this pre-calculated value verbatim, do NOT change it
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The FDA Fast Track designation for 'Varseta-M', an antibody-drug conjugate (ADC) for colorectal cancer treatment, is expected to streamline future development and review processes.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-27)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.